stockportfolio.pro
Stocks / TVTX vs TWST
TVTX vs TWST
Travere Therapeutics, Inc. and Twist Bioscience Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Travere Therapeutics, Inc. (TVTX) | Twist Bioscience Corporation (TWST) | |
|---|---|---|
| Market cap | $4.5B | $4.4B |
| Revenue (latest FY) | $490.73M | $376.57M |
| Net income (latest FY) | $-25.55M | $-77.67M |
| Revenue growth (5y CAGR) | 19.9% | 33.1% |
| Net margin | -5.2% | -20.6% |
| Return on equity | -22.2% | -16.4% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open TVTX — free Open TWST — freeFrequently asked questions
Which is bigger, TVTX or TWST?
Travere Therapeutics, Inc. is larger by market capitalization — $4.5B versus $4.4B.
Which grows faster, TVTX or TWST?
Over the last five fiscal years, Twist Bioscience Corporation grew revenue faster — 33.1%/yr versus 19.9%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.